Corvus Pharmaceuticals CRVS
$9.67 −$0.34 (-3.40%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $9.67 0.00%
Open$9.84
Prev close$10.01
Day range$9.56 – $10.04
Volume927.5K
Market cap$815.69M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$21.36M-102.1% YoY
Net profit-$20.34M-100.3% YoY
Diluted EPS-$0.22-83.3% YoY
Free cash flow-$12.28M-28.4% YoY
Operating cash flow-$12.22M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-45.9%
Return on assets-42.3%
Return on invested capital-50.2%
Current ratio13.38
Liabilities / assets6.9%
Cash & investments$202.95M
Total debt$139,000.00
Net cash (debt)$202.81M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $21.36M | $19.30M | $14.88M | $42.97M | $12.22M |
| Selling and Admin Expenses | $3.58M | $3.33M | $3.70M | $9.25M | $2.28M |
| -General & Admin Expense | $3.58M | $3.33M | $3.70M | $9.25M | $2.28M |
| Research & Development | $17.78M | $15.96M | $11.18M | $33.72M | $9.94M |
| Operating Profit | -$21.36M | -$19.30M | -$14.88M | -$42.97M | -$12.22M |
| Net Non-Operating Interest Income (Expense) | $1.91M | $2.05M | $1.78M | $2.51M | $603,000.00 |
| Non-Operating Interest Income | $1.91M | $2.05M | $1.78M | $2.51M | $603,000.00 |
| Other Income (Expense) | -$891,000.00 | -$709,000.00 | -$599,000.00 | $25.18M | -$707,000.00 |
| Earnings from Equity Interest | -$891,000.00 | -$709,000.00 | -$599,000.00 | -$1.96M | -$707,000.00 |
| Pretax Profit | -$20.34M | -$17.96M | -$13.69M | -$15.28M | -$12.32M |
| Net Profit | -$20.34M | -$17.96M | -$13.69M | -$15.28M | -$12.32M |
| Profit from Continuing Operations | -$20.34M | -$17.96M | -$13.69M | -$15.28M | -$12.32M |
| Net Income to Parent Company | -$20.34M | -$17.96M | -$13.69M | -$15.28M | -$12.32M |
| Net Income to Common Stockholders | -$20.34M | -$17.96M | -$13.69M | -$15.28M | -$12.32M |
| Basic EPS | -$0.22 | -$0.19 | -$0.15 | -$0.19 | -$0.15 |
| Diluted EPS | -$0.22 | -$0.19 | -$0.15 | -$0.53 | -$0.15 |
| Gain on Sale of Security | – | – | – | $27.14M | $0.00 |
| Special Income (Charges) | – | – | – | $0.00 | – |
| -Gain on Sale of Property/Plant/Equipment | – | – | – | $0.00 | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $223.88M | $239.27M | $253.20M | $71.12M | $71.12M |
| Total Current Assets | $206.35M | $220.97M | $239.95M | $58.21M | $58.21M |
| Cash and Cash Equivalents & Short-Term Investments | $202.95M | $215.23M | $236.71M | $56.75M | $56.75M |
| -Cash and Cash Equivalents | $15.01M | $18.91M | $40.10M | $4.58M | $4.58M |
| -Short Term Investments | $187.93M | $196.32M | $196.61M | $52.17M | $52.17M |
| Receivables | $1.29M | $1.85M | $1.20M | $374,000.00 | $374,000.00 |
| -Accounts Receivable | $5,000.00 | $6,000.00 | $43,000.00 | $37,000.00 | $37,000.00 |
| -Accrued Interest Receivable | $1.28M | $1.84M | $1.16M | $337,000.00 | $337,000.00 |
| Prepaid Assets | $1.80M | $3.31M | $1.67M | $772,000.00 | $772,000.00 |
| Other Current Assets | $317,000.00 | $575,000.00 | $367,000.00 | $318,000.00 | $318,000.00 |
| Total Non-Current Assets | $17.53M | $18.31M | $13.25M | $12.91M | $12.91M |
| Net PPE | $1.36M | $1.49M | $1.03M | $1.06M | $1.06M |
| -Gross PPE | $4.17M | $4.20M | $3.71M | $3.71M | $3.71M |
| -Accumulated Depreciation | -$2.81M | -$2.71M | -$2.68M | -$2.65M | -$2.65M |
| Investments and Advances | $14.47M | $15.11M | $10.50M | $10.99M | $10.99M |
| -Long Term Equity Investment | $14.47M | $15.11M | $10.50M | $10.99M | $10.99M |
| Other Non-Current Assets | $1.70M | $1.71M | $1.72M | $855,000.00 | $855,000.00 |
| Total Liabilities | $15.56M | $13.95M | $12.52M | $9.91M | $9.91M |
| Total Current Liabilities | $15.42M | $13.67M | $12.11M | $9.38M | $9.38M |
| Payables | $5.65M | $4.05M | $4.70M | $2.49M | $2.49M |
| -Accounts Payable | $5.65M | $4.05M | $4.70M | $2.49M | $2.49M |
| Current Accrued Expenses | $7.06M | $6.94M | $5.40M | $5.61M | $5.61M |
| Short-Term Debt and Capital Lease Obligation | $493,000.00 | $454,000.00 | $428,000.00 | $403,000.00 | $403,000.00 |
| -Current Capital Lease Obligation | $493,000.00 | $454,000.00 | $428,000.00 | $403,000.00 | $403,000.00 |
| Other Current Liabilities | $367,000.00 | $299,000.00 | $206,000.00 | $238,000.00 | $238,000.00 |
| Total Non-Current Liabilities | $139,000.00 | $274,000.00 | $406,000.00 | $534,000.00 | $534,000.00 |
| Long Term Debt and Capital Lease Obligation | $139,000.00 | $274,000.00 | $406,000.00 | $534,000.00 | $534,000.00 |
| -Long Term Capital Lease Obligation | $139,000.00 | $274,000.00 | $406,000.00 | $534,000.00 | $534,000.00 |
| Total Equity | $208.32M | $225.33M | $240.68M | $61.21M | $61.21M |
| Stockholders' Equity | $208.32M | $225.33M | $240.68M | $61.21M | $61.21M |
| Capital Stock | $8,000.00 | $8,000.00 | $8,000.00 | $7,000.00 | $7,000.00 |
| -Common Stock | $8,000.00 | $8,000.00 | $8,000.00 | $7,000.00 | $7,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $674.19M | $670.56M | $667.78M | $474.39M | $474.39M |
| Retained Earnings | -$464.29M | -$443.94M | -$425.99M | -$412.29M | -$412.29M |
| Gains/Losses Not Affecting Retained Earnings | -$1.59M | -$1.29M | -$1.13M | -$896,000.00 | -$896,000.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$12.22M | -$15.40M | -$10.37M | -$32.80M | -$9.19M |
| Net cash flow from continuing operations | -$12.22M | -$15.40M | -$10.37M | -$32.80M | -$9.19M |
| Net Income from Continuing Operations | -$20.34M | -$17.96M | -$13.69M | -$15.28M | -$12.32M |
| Gain/Loss from Continuing Operations | $891,000.00 | $709,000.00 | $599,000.00 | -$25.18M | $707,000.00 |
| Depreciation & Depletion & Amortization | $95,000.00 | $34,000.00 | $29,000.00 | $105,000.00 | $26,000.00 |
| Change in Working Capital | $4.06M | -$976,000.00 | $57,000.00 | $3.58M | $1.08M |
| -Change in Receivables | $1,000.00 | $37,000.00 | -$6,000.00 | $38,000.00 | -$5,000.00 |
| -Change in Prepaid Assets | $2.34M | -$2.54M | -$1.76M | $941,000.00 | -$204,000.00 |
| -Change in Payables and Accrued Expense | $1.71M | $1.54M | $2.71M | $2.67M | $1.28M |
| -Change in Other Current Assets | $106,000.00 | $99,000.00 | -$777,000.00 | $115,000.00 | $85,000.00 |
| -Change in Other Current Liabilities | -$96,000.00 | -$106,000.00 | -$103,000.00 | -$185,000.00 | -$74,000.00 |
| Net cash flow from investing | $7.52M | -$5.97M | -$144.85M | -$7.80M | $10.88M |
| Net Cash Flow from Continuing Investing Activities | $7.52M | -$5.97M | -$144.85M | -$7.80M | $10.88M |
| Net PPE Purchase and Sale | -$66,000.00 | -$582,000.00 | -$91,000.00 | -$174,000.00 | -$25,000.00 |
| Net Business Purchase and Sale | $0.00 | – | – | – | – |
| Net Investment Purchase and Sale | $7.58M | -$383,000.00 | -$144.76M | -$7.62M | $10.91M |
| Financing Cash Flow | $805,000.00 | $166,000.00 | $190.75M | $36.43M | $20,000.00 |
| Net Cash Flow from Continuing Financing Activities | $805,000.00 | $166,000.00 | $190.75M | $36.43M | $20,000.00 |
| Net Common Stock Issuance | $0.00 | $0.00 | $189.41M | $0.00 | $0.00 |
| Proceeds from Stock Option Exercised | $805,000.00 | $166,000.00 | $1.34M | $36.43M | $20,000.00 |
| Ending Cash Balance | $15.01M | $18.91M | $40.10M | $4.58M | $4.58M |
| Net Change in Cash | -$3.89M | -$21.20M | $35.53M | -$4.16M | $1.71M |
| Beginning Cash Balance | $18.91M | $40.10M | $4.58M | $8.74M | $2.87M |
| Free Cash Flow | -$12.28M | -$15.98M | -$10.47M | -$32.97M | -$9.22M |
No comments yet — be the first to weigh in on CRVS.
Sign in to join the discussion.